NVP-LEQ-506

DB12857InvestigationalSmall molecule

LEQ506 has been used in trials studying the treatment of Advanced Solid Tumors, Recurrent or Refractory Medulloblastoma, and Locally Advanced or Metastatic Basal Cell Carcinoma.

Mechanism: Pharmacologically active on Protein smoothened
Curator reviewed
Formula / weight: C₂₅H₃₂N₆O · 432.572 g/mol (avg)
Code names: LEQ-506 · NVP-LEQ506

Resolves to

Compound

UNII6SJX1T5HJDCAS1204975-42-7ChEMBLCHEMBL3133037PubChem45100669

Structure

InChIKeyPOERAARDVFVDLO-QGZVFWFLSA-NSMILESC[C@@H]1CN(CCN1C1=CN=C(C=N1)C(C)(C)O)C1=NN=C(CC2=CC=CC=C2)C(C)=C1C

Targets

Q99835SMO

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with NVP-LEQ-506, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account